Skip to main content
. 2022 May 24;9:895927. doi: 10.3389/fmolb.2022.895927

FIGURE 2.

FIGURE 2

Clinical significance of lncRNA-AP000695.2 in lung adenocarcinoma. (A) Expression of lncRNA-AP000695.2 in lung cancer based on TCGA dataset. (B) Expression levels of lncRNA-AP000695.2 in 59 paired adjacent normal tissues and paired samples. (C) Expression levels of lncRNA-AP000695.2 in lung cancer based on the GEO dataset. (D–G) Correlation between lncRNA-AP000695.2 expression and clinical parameters includes pathological and TNM stages. (H–I) ROC curves were used to determine the diagnostic value of lncRNA-AP000695.2 in lung adenocarcinoma based on TCGA-LUAD and GEO datasets. (J–L) Kaplan–Meier survival curves showed that lung adenocarcinoma patients with high-lncRNA-AP000695.2 expression exhibited poor overall survival, disease-specific survival, and progression-free survival based on TCGA-LUAD dataset. *p < 0.05, **p < 0.01, and ***p < 0.001.